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Editorial
Improving the external validity of clinical trials: the case of multiple 
chronic conditions
Martin Fortin1,2, Susan M. Smith3
1Department of Family Medicine, Université de Sherbrooke, Sherbrooke, Quebec, Canada; 2Centre de santé et de services 
sociaux de Chicoutimi, Chicoutimi, Quebec, Canada; 3HRB Centre for Primary Care Research, Department of General 
Practice, Royal College of Surgeons, Dublin, Ireland
Abstract
The U.S. Department of Health and Human Services vision and strategic framework on multiple chronic condi-
tions (MCCs) incorporates recommendations designed to facilitate research that will improve our knowledge 
about interventions and systems that will benefi t individuals with MCCs (or multimorbidity). The evidence base 
supporting the management of patients with MCCs will be built through intervention trials specifi cally designed 
to address multimorbidity and identifi cation of MCCs in participants across the clinical trial range. This article 
specifi cally focuses on issues relating to external validity with specifi c reference to trials involving patients with 
MCCs. The exclusion of such patients from clinical trials has been well documented. Randomized control trials 
(RCTs) are considered the “gold standard” of evidence, but may have drawbacks in relation to external validity, 
particularly in relation to multimorbidity. It may, therefore, be necessary to consider a broader range of research 
methods that can provide converging evidence on intervention effects to address MCCs. Approaches can also be 
taken to increase the usefulness of RCTs in general for providing evidence to inform multimorbidity manage-
ment. Additional improvements to RCTs would include better reporting of inclusion and exclusion criteria and 
participant characteristics in relation to MCCs. New trials should be considered in terms of how they will add 
to the existing evidence base and should inform how interventions may work in different settings and patient 
groups. Research on treatments and interventions for patients with MCCs is badly needed. It is important that 
this research includes patient-centered measures and that generalizability issues be explicitly addressed.
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Introduction
Enhancing the external validity of clinical trials is one 
of the priority areas identifi ed in the initiative launched 
by the U.S. Department of Health and Human Services 
(HHS) to strengthen efforts to address the challenge 
of the rising prevalence of multiple chronic condi-
tions (MCCs), or multimorbidity, in the population 
[1]. This article specifi cally focuses on issues relating 
to external validity of evidence, with specifi c reference 
to trials involving patients with MCCs. We also con-
sider some potential solutions to address the problem of 
low external validity of clinical trials for these patients. 
There are two distinct scenarios in relation to trials 
and multimorbidity. The fi rst occurs where a trial has 
been specifi cally designed to test an intervention that 
addresses MCCs [2,3] and the second relates to the like-
lihood that participants in most clinical trials are likely 
to have multimorbidity to some extent and the question 
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is how generalizable the results of that trial are to all 
patients with MCCs. The challenge inherent to research 
in multimorbidity is that there is heterogeneity within 
the group. At its simplest level, MCCs includes patients 
with clear comorbid conditions, but this then expands 
out to more general multimorbidity, in which there is no 
prespecifi ed index condition and there are multiple pos-
sible combinations and permutations of conditions and 
condition severity [4].
External validity, sometimes also referred to as 
generalizability, describes the applicability of interven-
tions in settings beyond the original study. However, 
determining the external validity of a study is more 
diffi cult than determining its counterpart, internal 
validity. Internal validity describes the degree to which 
the design and conduct of a trial reduces the possibil-
ity of bias within that trial, and it can be judged using 
the list of items in guidelines on trial methodology 
and reporting, such as the CONSORT (Consolidated 
Standards of Reporting Trials) statement [5]. Deter-
mining whether the results of a trial are valid for 
patients other than those in the original study popu-
lation requires detailed information on participant 
characteristics, clinical expertise, and an understanding 
of healthcare systems and settings, rather than statis-
tical or methodological expertise [6]. External validity 
is considered a complex concept [6,7], and has been 
defi ned as “the overarching descriptor for all aspects of 
the design and performance that impact on the exter-
nal usefulness of the result of a trial, independent of the 
‘internal validity’ of the trial” [6].
General aspects that may impact on the external 
validity of trials can be divided into system and patient 
factors. Patient factors are refl ected in the selection of 
patients and the potential differences between enrolled 
patients and the general patient population [6]. Sys-
tem factors include the setting of the trial, differences 
between trial protocol and routine practice, and poten-
tial impact of the intervention on service organization 
and costs for patients and providers, which, in turn, 
depend on fi nancing within health systems. While there 
is a clear need for further studies of interventions in 
patients with multimorbidity [8], this paper specifi cally 
focuses on issues relating to external validity which are 
particularly relevant for those with MCCs.
Challenges to external validity
One of the main challenges to external validity of trials 
is that most clinical trials targeting chronic conditions 
would fi nd a high number of patients with MCCs dur-
ing the recruitment process [9]. This situation applies 
particularly to trials involving patients in primary care 
settings because it is known that patients with MCCs 
constitute the majority of patients in this setting [10]. 
Nevertheless, the potential exclusion of such patients 
from clinical trials has been well documented [11,12]. 
Clinical trials should provide evidence to inform policy 
and practice regarding new treatments and interven-
tions for all patients. This can be addressed either by 
specifi cally designing trials to test interventions that 
address multimorbidity or, in these trials, reporting 
of participant characteristics and intervention set-
tings and components allowing for an interpretation 
of external validity. It is more diffi cult, in general, in 
clinical trials, where exclusion of patients with MCCs 
means that important information about the proper 
use of a treatment or intervention for those patients is 
not available. In other words, the exclusion of patients 
with MCCs limits the external validity of clinical tri-
als for these patients [13–16]. However, many of these 
trials may have included patients with MCCs, but not 
identifi ed them as such, and this is a problem frequently 
observed in reports of clinical trials where there is low 
reporting of data around participant characteristics 
that could have informed external validity [13,17]. 
For example, in a randomized trial of peer support 
for patients with type 2 diabetes, a secondary analy-
sis of characteristics of all included patients indicated 
that 90% had MCCs, with 25% having four or more 
conditions. Within the cohort of 424 patients, there 
were 189 unique conditions [18]. This highlights the 
importance of fully reporting participant characteris-
tics to facilitate a complete and correct interpretation 
of the generalizability of the trial’s results. Table 1 
highlights other potential challenges to external valid-
ity, including whether patients with MCCs will agree 
to participate in clinical trials as they may already be 
overburdened by treatment and healthcare attendances 
[19]. Additionally, interventions may have a single-
condition focus, making them of less interest and use 
to patients with MCCs, or there may be costs involved 
to intervention participation that act as a deterrent to 
those already experiencing high health service utiliza-
tion and costs [20,21].
When seeking to fi nd ways to improve the exter-
nal validity of clinical trials for patients with MCCs, 
one soon encounters a barrier relating to the poten-
tial imbalance between internal and external validity 
in randomized controlled trials (RCTs) [22]. It can be 
argued that internal validity is a prerequisite for exter-
nal validity as there is no point in trying to generalize 
evidence from a poor-quality trial [23]. RCTs are 
considered the “gold standard” of evidence because of 
their ability to reduce selection bias and other factors 
that could bias outcomes, so researchers usually aim to 
enhance internal validity by having replicable and clear 
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patient inclusion criteria that may lead to the exclusion 
of medically complex subjects. However, this will likely 
be at the cost of reducing external validity, which may 
initially seem to be of secondary importance. Results 
regarding the effectiveness of the intervention tested 
in an RCT with high internal validity will be more 
robust, but they will probably provide limited evidence 
to support care for patients with MCCs found in real 
life. A consequence of poor external validity of clinical 
trials is that clinical practice guidelines, which are often 
based primarily on expert review of the hierarchy of 
evidence from relevant clinical trials, can have limited 
utility for patients with MCCs or may lead to inap-
propriate use of interventions in these patients [24,25].
Potential solutions
In the initiative launched by the HHS, one of the objec-
tives identifi ed within the goal of facilitating research to 
fi ll knowledge gaps was to enhance the external validity 
of clinical trials. To meet this goal, four objectives were 
outlined: (i) to develop methods to assess the inclusion of 
individuals with MCCs in clinical trials; (ii) to improve 
the external validity of trials by ensuring that individu-
als with MCCs are not unnecessarily excluded; (iii) to 
ensure that individuals with MCCs are not unnecessarily 
excluded from clinical trials for the approval of prospec-
tive drugs and devices; and (iv) to assess and strengthen 
postmarketing surveillance for potential interven-
tion-related adverse effects and poor outcomes among 
individuals with MCCs. To increase the external validity 
of trials for individuals with MCCs is a challenging task 
and can be considered in individual areas.
Consider alternative and complementary designs 
for trials in MCCs
Some possible solutions have been proposed to 
enhance the external validity of RCTs in general 
[22,26–28]. Within this ongoing discussion, Kaplan 
and colleagues [27] made an interesting point when 
they said, “evidence based medicine has made a 
leap from considering RCTs to be a high standard 
to being the only standard”. This suggests that we 
may need to reconsider our over-reliance on RCTs 
to measure intervention effects and make a greater 
use of alternative forms of evidence, particularly for 
patients with MCCs. Use of mixed research methods, 
i.e. combining experimental designs with parallel 
qualitative process evaluations, can provide converg-
ing evidence on intervention effects and may be a 
good way to address the problem of external valid-
ity. The accumulated evidence about an intervention 
would be gathered from a combination of RCTs and 
other methods that would provide more informa-
tion to support the judgements related to external 
validity for patients with MCCs. Alternative designs 
Table 1 Issues related to the external validity of trials involving patients with multiple chronic conditions (MCCs).
Issue  Potential solution
Patient factors
 Lack of clarity around participant inclusion and defi nitions Need to have clear defi nitions of MCCs – whether derived from health record 
or patient report; condition counts vs. condition severity scores and whether 
restricted lists of included conditions applied
 Participants with MCCs are less likely to consent to 
participate if disease burden is too high or if in poor 
health
 Consider minimizing burden of participation in intervention
 Participants with MCCs may see single-condition trial as 
being less relevant to them
 Consider interventions that are not condition specifi c or that address specifi c 
concerns of MCCs, such as functional or physical performance
 Prespecifi ed ancillary analyses taking into account patients’ 
heterogeneity
 Consider preplanning subgroup analyses based on condition counts, severity, and 
condition combinations
 Age of participants with MCCs  Interventions for middle-aged adults with MCCs who are still working may need 
to be quite different from those for older participants
System factors
 Chronic disease interventions designed around single 
conditions
 Consider more generalized interventions, such as medicines management or 
support for self-management
 Setting: primary vs. specialty care setting  Patient populations and clinicians will be quite different in both settings, but this 
may be less of an issue for patients with MCCs who commonly attend multiple 
healthcare providers
 System fi nancing issues  Avoid interventions that increase direct or indirect costs to patients or providers
 Organizational setting  Intervention embedded in the system that refl ects usual care for patients
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could also be considered [3]. For example, this could 
include crossover trials with patients serving as their 
own controls with periods of intervention and no 
intervention distributed at random where interven-
tions are not thought to have sustained effects beyond 
their delivery. Nevertheless, alternative study designs 
are not the panacea as they may be compromised by 
bias and all new trials should be considered in terms 
of how they will add to the existing evidence base. 
This emphasizes the importance of conducting trials 
using designs that will ultimately be incorporated in 
new updates of systematic reviews [29].
Consider external validity when designing and 
reporting current RCTs
In pragmatic, randomized clinical trials, the aim is 
to establish the effectiveness rather than the effi -
cacy of interventions. Participants who are similar to 
patients typically seen by clinicians in routine practice 
are therefore included to achieve a balance between 
pragmatism and individualization of interventions 
and generalizability. This addresses the HSS strategy 
on the inclusion of individuals with MCCs in clini-
cal trials. Funders of RCTs could emphasize the need 
to maximize external validity of RCTs in relation to 
MCCs as an important condition for fi nancing studies, 
as suggested in Strategy 2 of the HHS. RCTs would 
have greater external validity if researchers tried to fi nd 
an adequate balance between the demonstrated ben-
efi t in ideal conditions in samples of patients with no 
coexisting health problems, and benefi t in the broader 
population under less ideal circumstances [27]. This 
balance should also be refl ected in clinical trials for the 
approval of prospective drugs and devices, as outlined 
in Strategy 3 of the HHS.
Consider alternative sources of evidence
Postmarketing surveillance of drugs as well as collection 
and analysis of administrative clinical data about interven-
tions being applied to patients with MCCs would also 
provide valuable evidence. This is in agreement with the 
HHS strategy on strengthening post-marketing surveil-
lance for potential intervention-related adverse effects 
and poor outcomes among individuals with MCCs. In 
some situations, expert opinions about the management 
of patients with MCCs passed down through consensus 
guidelines may be the only available source of “evidence”. 
Qualitative methods, treatment fi delity analysis, and epi-
demiological data, including prospective cohort studies, 
are other examples of additional sources of informa-
tion, particularly around potential harm, as this generally 
requires larger sample sizes than generally found in RCTs. 
We believe that the acceptance of a new drug in the mar-
ket as well as a new intervention in practice should rely 
on multiple sources of evidence incorporating data on 
patients with MCCs and not just be reliant on evidence 
from RCTs. This would help to ensure that individuals 
with MCCs are not unnecessarily excluded from evidence 
base for the approval of drugs and devices, as outlined in 
Strategy 3 of the HHS.
Consider secondary data analysis of existing trial 
evidence
Another approach to enhance the current evidence base 
to support management of MCCs would be to conduct 
secondary analyses of existing trial databases using avail-
able data relating to MCCs. This could be conducted by 
increasing trial datasets that are made available for public 
access, particularly for trials funded through government 
agencies [30]. This would provide further evidence of the 
potential effectiveness of the intervention in patients with 
MCCs. These analyses could be based on existing infor-
mation on chronic conditions, but if this is not available, 
there may be other information in trial databases, such 
as counts of prescribed medicines, which can be a good 
proxy for MCCs [31].
The issues related to the external validity of clinical tri-
als and possible solutions are summarized in Table 1. The 
key issue is that recruitment of patients with MCCs to 
trials will make RCTs more informative about the health 
impacts of a new intervention for the broader population.
Concluding remarks
We have addressed the need to consider patients with 
MCCs, both in the evaluation of trials testing new health 
interventions generally and in trials testing interventions 
specifi cally designed to address multimorbidity. So far, 
the majority of research on interventions in MCCs has 
focused on organizational aspects of health care [32]. 
Further research on treatments for patients with MCCs is 
badly needed [2,32]. However, to do specifi c research on 
MCCs, we have to think about different ways of devel-
oping and adapting the evidence base to enhance clinical 
care and patient outcomes. We should also focus the 
interventions on patient-identifi ed problems, which will 
mean involving patients and care providers in decision-
making about which interventions to test [26]. Clinicians 
need evidence-based guidelines to support treatments, 
and these need to be informed by trials of treatments and 
interventions that refl ect the priorities of patients and 
healthcare providers and can be generalized to support 
care for those living with and managing MCCs.
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